Body Weight Cutoff for Daily Dosage of Efavirenz and 60-Week Efficacy of Efavirenz-Based Regimen in Human Immunodeficiency Virus and Tuberculosis Coinfected Patients Receiving Rifampin

• Published in: Antimicrobial Agents and Chemotherapy Vol. 53; no. 10; pp. 4545 - 4548
• Main Authors: MANOSUTHI, Weerawat, SUNGKANUPARPH, Somnuek, RUXRUNGTHAM, Kiat, TANTANATHIP, Preecha, MANKATITHAM, Wiroj, LUEANGNIYOMKUL, Aroon, THONGYEN, Supeda, EAMPOKARAP, Boonchuay, UTTAYAMAKUL, Sumonmal, SUWANVATTANA, Pawita, KAEWSAARD, Samroui
• Format: Journal Article
• Language: English
• Published: Washington, DC American Society for Microbiology 01.10.2009; American Society for Microbiology (ASM)
• Subjects: Anti-HIV Agents - administration & dosage; Anti-HIV Agents - therapeutic use; Antibiotics, Antitubercular - administration & dosage; Antibiotics, Antitubercular - therapeutic use; Antibiotics. Antiinfectious agents. Antiparasitic agents; Antiviral Agents; Bacterial diseases; Benzoxazines; Benzoxazines - administration & dosage; Benzoxazines - therapeutic use; Biological and medical sciences; Body Weight; Drug Administration Schedule; Efavirenz; Fasting; Female; HIV Infections; HIV Infections - drug therapy; Human bacterial diseases; Human immunodeficiency virus; Human viral diseases; Humans; Immunodeficiencies; Immunodeficiencies. Immunoglobulinopathies; Immunodeficiency; Immunopathology; Infectious diseases; Male; Medical sciences; Multivariate Analysis; Mycobacterium; Pharmacology. Drug treatments; Rifampin; Rifampin - administration & dosage; Rifampin - therapeutic use; Standard deviation; Tuberculosis; Tuberculosis - drug therapy; Tuberculosis and atypical mycobacterial infections; Viral diseases; Viral diseases of the lymphoid tissue and the blood. Aids; Antiretroviral agent; Benzoxazine derivatives; RNA-directed DNA polymerase; Mixed infection; Acetylenic compound; Non nucleoside compound; Body weight; Mycobacterial infection; Efavirenz; Rifampicin; Reverse transcriptase inhibitor; Antiviral; Antituberculous agent; Protein synthesis inhibitor; Human; Immunopathology; Enzyme; Transferases; Treatment efficiency; Enzyme inhibitor; Retroviridae; Patient; AIDS; Immune deficiency; Lentivirus; Infection; Virus; Allosteric inhibitor; Nucleotidyltransferases; Antibiotic; Tuberculosis; Viral disease; Bacteriosis; Human immunodeficiency virus; Antibacterial agent; Therapeutic protocol
• ISSN: 0066-4804; 1098-6596
• DOI: 10.1128/AAC.00492-09

Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit StumbleUpon Twitter current issue AAC About AAC Subscribers Authors Reviewers Advertisers Inquiries from the Press Permissions & Commercial Reprints ASM Journals Public Access Policy AAC RSS Feeds 1752 N Street N.W. • Washington DC 20036 202.737.3600 • 202.942.9355 fax • journals@asmusa.org Print ISSN: 0066-4804 Online ISSN: 1098-6596 Copyright © 2014 by the American Society for Microbiology.   For an alternate route to AAC .asm.org, visit: AAC